Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study

Journal of Psychiatric Research

Volumn 53, Issue 1, 2014, Pages 133-140

  Modabbernia, Amirhossein ^a   Heidari, Parvaneh ^b   Soleimani, Robabeh ^b   Sobhani, Abdolrasoul ^c   Roshan, Zahra Atrkar ^c   Taslimi, Shervin ^a,d   Ashrafi, Mandana ^a   Modabbernia, Mohammad Jafar ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glucose; Lipid; Melatonin; Olanzapine; Schizophrenia; Weight gain

Indexed keywords

CHOLESTEROL; CLONAZEPAM; FASTING BLOOD SUGAR; FASTING INSULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MELATONIN; OLANZAPINE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIOXIDANT; BENZODIAZEPINE DERIVATIVE; LIPID; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ADOLESCENT; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BEDTIME DOSAGE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HOMEOSTATIC MODEL FOR ASSESSMENT OF INSULIN RESISTANCE TOOL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN; YOUNG ADULT; BLOOD; CHEMICALLY INDUCED; METABOLIC DISEASES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIPIDS; MALE; MELATONIN; METABOLIC DISEASES; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897388149     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.02.013     Document Type: Article

References (48)

1. Agil A., Navarro-Alarcon M., Ruiz R., Abuhamadah S., El-Mir M.Y., Vazquez G.F. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. JPineal Res 2011, 50:207-212.
2. Alonso-Vale M.I., Peres S.B., Vernochet C., Farmer S.R., Lima F.B. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. JPineal Res 2009, 47:221-227.
3. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012, 27:113-119.
4. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. JClin Psychiatry 2003, 64:598-604.
5. Baptista T., ElFakih Y., Uzcategui E., Sandia I., Talamo E., Araujo de Baptista E., et al. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008, 22:477-495.
6. Bender R., Lange S. Adjusting for multiple testing - when and how?. JClin Epidemiol 2001, 54:343-349.
7. Borba C.P., Fan X., Copeland P.M., Paiva A., Freudenreich O., Henderson D.C. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. JClin Psychopharmacol 2011, 31:653-658.
8. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999, 29:697-701.
9. Cagnacci A., Arangino S., Renzi A., Paoletti A.M., Melis G.B., Cagnacci P., et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf) 2001, 54:339-346.
10. Citrome L., Kantrowitz J.T. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?. Expert Rev Neurother 2009, 9:1045-1058.
11. Coccurello R., Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010, 127:210-251.
12. Cohrs S. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics. CNS Drugs 2008, 22:939-962.
13. Everson C.A. Functional consequences of sustained sleep deprivation in the rat. Behav Brain Res 1995, 69:43-54.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition 2002, Biometrics Research, New York State Psychiatric Institute, New York.
15. Gonciarz M., Bielanski W., Partyka R., Brzozowski T., Konturek P.C., Eszyk J., et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. JPineal Res 2013, 54:154-161.
16. Hussein M.R., Ahmed O.G., Hassan A.F., Ahmed M.A. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol 2007, 88:19-29.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
18. Korkmaz A., Topal T., Tan D.X., Reiter R.J. Role of melatonin in metabolic regulation. Rev Endocr Metab Disord 2009, 10:261-270.
19. Kozirog M., Poliwczak A.R., Duchnowicz P., Koter-Michalak M., Sikora J., Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. JPineal Res 2011, 50:261-266.
20. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEngl J Med 2005, 353:1209-1223.
21. Lucassen E.A., Rother K.I., Cizza G. Interacting epidemics? Sleep curtailment, insulin resistance, and obesity. Ann N Y Acad Sci 2012, 1264:110-134.
22. Markwald R.R., Melanson E.L., Smith M.R., Higgins J., Perreault L., Eckel R.H., et al. Impact of insufficient sleep on total daily energy expenditure, food intake, and weight gain. Proc Natl Acad Sci U S A 2013, 110:5695-5700.
23. Martin M., Macias M., Leon J., Escames G., Khaldy H., Acuna-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002, 34:348-357.
24. McElroy S.L., Winstanley E., Mori N., Martens B., McCoy J., Moeller D., et al. Arandomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. JClin Psychopharmacol 2012, 32:165-172.
25. Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. JMol Neurosci 2011, 45:304-308.
26. Patel J.K., Buckley P.F., Woolson S., Hamer R.M., McEvoy J.P., Perkins D.O., et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009, 111:9-16.
27. Peschke E., Muhlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab 2010, 24:829-841.
28. Pramyothin P., Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010, 17:460-466.
29. Prunet-Marcassus B., Desbazeille M., Bros A., Louche K., Delagrange P., Renard P., et al. Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity. Endocrinology 2003, 144:5347-5352.
30. Ramracheya R.D., Muller D.S., Squires P.E., Brereton H., Sugden D., Huang G.C., et al. Function and expression of melatonin receptors on human pancreatic islets. JPineal Res 2008, 44:273-279.
31. Raskind M.A., Burke B.L., Crites N.J., Tapp A.M., Rasmussen D.D. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 2007, 32:284-288.
32. Reiter R.J., Tan D.X., Korkmaz A., Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med 2012, 44:564-577.
33. Rindone J.P., Achacoso R. Effect of melatonin on serum lipids in patients with hypercholesterolemia: a pilot study. Am J Ther 1997, 4:409-411.
34. Rios-Lugo M.J., Cano P., Jimenez-Ortega V., Fernandez-Mateos M.P., Scacchi P.A., Cardinali D.P., et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. JPineal Res 2010, 49:342-348.
35. Robeva R., Kirilov G., Tomova A., Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. JPineal Res 2008, 44:52-56.
36. Ruger M., Scheer F.A. Effects of circadian disruption on the cardiometabolic system. Rev Endocr Metab Disord 2009, 10:245-260.
37. Sandyk R. The relationship of thought disorder to third ventricle width and calcification of the pineal gland in chronic schizophrenia. Int J Neurosci 1993, 68:53-59.
38. Scheer F.A., Van Montfrans G.A., van Someren E.J., Mairuhu G., Buijs R.M. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43:192-197.
39. Seabra M.L., Bignotto M., Pinto L.R., Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. JPineal Res 2000, 29:193-200.
40. Strassnig M., Miewald J., Keshavan M., Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007, 93:90-98.
41. Tan D.X., Manchester L.C., Fuentes-Broto L., Paredes S.D., Reiter R.J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011, 12:167-188.
42. Tsai M.C., Chen W.J., Tsai M.S., Ching C.H., Chuang J.I. Melatonin attenuates brain contusion-induced oxidative insult, inactivation of signal transducers and activators of transcription 1, and upregulation of suppressor of cytokine signaling-3 in rats. JPineal Res 2011, 51:233-245.
43. Tups A., Ellis C., Moar K.M., Logie T.J., Adam C.L., Mercer J.G., et al. Photoperiodic regulation of leptin sensitivity in the Siberian hamster, Phodopus sungorus, is reflected in arcuate nucleus SOCS-3 (suppressor of cytokine signaling) gene expression. Endocrinology 2004, 145:1185-1193.
44. Uzbay T., Parlakpinar H., Akdag E., Celik T., Yararbas G., Ulusoy G., et al. Chronic melatonin treatment reverses disruption of prepulse inhibition in pinealectomized and pinealectomized-plus-ovariectomized rats. Behav Brain Res 2013, 239:1-7.
45. Weil Z.M., Hotchkiss A.K., Gatien M.L., Pieke-Dahl S., Nelson R.J. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res Bull 2006, 68:425-429.
46. Wolden-Hanson T., Mitton D.R., McCants R.L., Yellon S.M., Wilkinson C.W., Matsumoto A.M., et al. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000, 141:487-497.
47. Wu R.R., Zhao J.P., Guo X.F., He Y.Q., Fang M.S., Guo W.B., et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008, 165:352-358.
48. Zanuto R., Siqueira-Filho M.A., Caperuto L.C., Bacurau R.F., Hirata E., Peliciari-Garcia R.A., et al. Melatonin improves insulin sensitivity independently of weight loss in old obese rats. JPineal Res 2013, 55:156-165.